Olumiant (baricitinib) is a small molecule pharmaceutical. Baricitinib was first approved as Olumiant on 2017-02-13. It is used to treat rheumatoid arthritis in the USA. It has been approved in Europe to treat rheumatoid arthritis. The pharmaceutical is active against tyrosine-protein kinase JAK2 and tyrosine-protein kinase JAK1. In addition, it is known to target cyclin-G-associated kinase, non-receptor tyrosine-protein kinase TYK2, BMP-2-inducible protein kinase, AP2-associated protein kinase 1, and tyrosine-protein kinase JAK3. Olumiant's patents are valid until 2030-06-08 (FDA).
|Drug Class||Tyrosine kinase inhibitors: janus kinase inhibitors|